![]() |
|||

Breast cancer
Ovarian cancer
Skin cancer
Degratation
Biol Chem. 2006 Dec;387(12):1607-12. The
role of human tissue kallikreins 7 and 8 in
intracranial malignancies. ¡P
Prezas
P, Scorilas
A, Yfanti
C, Viktorov
P, Agnanti
N, Diamandis
E, Talieri
M. G. Papanicolaou
Research Center of Oncology, Saint Savas
Hospital, 171 Alexandras Avenue, GR-11522 Athens,
Greece. Recent evidence suggests that many tissue kallikreins are implicated in carcinogenesis. Kallikrein 8 (KLK8) plays a role in the physiology of
the central nervous system. Kallikrein 7 (KLK7)
takes part in skin desquamation. Both show altered expression in ovarian
and breast cancer. In this study, we examined the level of mRNA expression
of the KLK7 and KLK8 genes in 73 intracranial tumors using qualitative
RT-PCR. The results were correlated with clinical and histomorphological
variables and patient outcome. The expression of both genes was also
examined in the brain cancer cell lines U-251 MG, D54 and SH-SY5Y and the
invasive capacity of glioblastoma cells U-251 MG overexpressing hK7 or hK8 was also investigated in an
in vitro Matrigel assay. Follow-up analysis
revealed that expression of KLK7 mRNA was associated with shorter overall
survival (OS) compared to patients with no KLK7 expression, as determined
by Cox proportional hazard regression analysis. Overexpression
of hK7 protein by cultivated brain tumor cells significantly enhanced the
invasive potential in the Matrigel invasion
assay, in contrast to cells overexpressing hK8
protein. Our data suggest that hK7 protein overexpression
is associated with a more aggressive phenotype in brain cancer cells. FEBS Lett. 2005 Dec 19;579(30):6879-84.
Epub 2005 Dec 1. Biochemical
characterization of human kallikrein 8 and its possible
involvement in the degradation of extracellular
matrix proteins. ¡P
Rajapakse
S, Ogiwara
K, Takano N, Moriyama A,
Takahashi T.
Division of Biological
Sciences, Human kallikrein 8 (KLK8) is
a member of the human kallikrein gene family of
serine proteases, and its protein, hK8, has recently been suggested to
serve as a new ovarian cancer marker. To gain insights into the
physiological role of hK8, the active recombinant enzyme was obtained in a
pure state for biochemical and enzymatic characterizations. hK8 had trypsin-like activity
with a strong preference for Arg over PMID: 16337200 [PubMed -
indexed for MEDLINE] PMID: 17132107 [PubMed - in
process] Clin Cancer Res. 2006 Mar 1;12(5):1487-93. Human kallikrein
8 protein is a favorable prognostic marker in ovarian cancer. ¡P
Borgono
CA, Kishi
T, Scorilas
A, Harbeck
N, Dorn J, Schmalfeldt
B, Schmitt M,
Diamandis
EP. Department of Pathology and
Laboratory Medicine, Human kallikrein 8
(hK8/neuropsin/ovasin; encoded by KLK8) is a steroid hormone-regulated
secreted serine protease differentially expressed in ovarian carcinoma.
KLK8 mRNA levels are associated with a favorable patient prognosis and hK8
protein levels are elevated in the sera of 62% ovarian cancer patients,
suggesting that KLK8/hK8 is a prospective biomarker. Given the above, the
aim of the present study was to determine if tissue hK8 bears any
prognostic significance in ovarian cancer. Using a newly developed ELISA,
hK8 was quantified in 136 ovarian tumor extracts and correlated with clinicopathologic variables and outcome
[progression-free survival (PFS); overall survival (OS)] over a median
follow-up period of 42 months. hK8 levels in
ovarian tumor cytosols ranged from 0 to 478 ng/mg total protein, with a median of 30 ng/mg. An optimal cutoff value of 25.8 ng/mg total protein (74th percentile) was selected
based on the ability of hK8 values to predict the PFS of the study
population and to categorize tumors as hK8 positive or negative. Women with
hK8-positive tumors most often had lower-grade tumors (G1), no residual
tumor after surgery, and optimal debulking
success (P < 0.05). Univariate and
multivariate analyses revealed that patients with hK8-positive tumors had a
significantly longer PFS and OS than hK8-negative patients (P < 0.05).
Kaplan-Meier survival curves further confirmed a reduced risk of relapse
and death in women with hK8-positive tumors (P = 0.001 and P = 0.014,
respectively). These results indicate that hK8 is an independent marker of
favorable prognosis in ovarian cancer. PMID: 16533772 [PubMed -
indexed for MEDLINE] Oncol Rep. 2004 Jun;11(6):1153-9. Human kallikrein
8 (hK8/TADG-14) expression is associated with an
early clinical stage and favorable prognosis in ovarian cancer. ¡P
Shigemasa
K, Tian
X, Gu
L, Tanimoto
H, Underwood LJ,
O'Brien TJ,
Ohama
K. Department of Obstetrics and
Gynecology, Hiroshima University Graduate School of Biomedical Sciences,
Minami-ku, The purpose of this study was to examine human kallikrein 8 (hK8/TADG-14) expression
in epithelial ovarian tumors and to investigate the association of hK8
expression levels with patient survival. Human kallikrein
8 protein (hK8) expression was examined by immunohistochemistry
in 74 ovarian adenocarcinomas and 6 normal
ovaries. Results of immunostaining were
correlated with clinicopathological variables and
overall survival of the patients. Human kallikrein
8 gene (KLK8) mRNA expression was examined by semi-quantitative PCR in 35
ovarian tumors and 7 normal ovaries. Expression of hK8 was not detected on
the surface epithelium of normal ovaries. In contrast, hK8 expression was
detected in 51.4% (38/74) of carcinomas with a significantly higher
detection rate of hK8 expression being observed in early stage disease compared
to advanced stage disease (p=0.0192). Data analysis using the log-rank test
showed hK8 expression correlated significantly with favorable patient
survival (p=0.0328). Younger age (p=0.0008), early clinical stage
(p<0.0001), and low histological grades of the tumors (p=0.0018) were
also associated significantly with a favorable prognosis. In a multivariate
model, age (p=0.0186) and clinical stage (p<0.0001) remained associated
significantly with overall survival, whereas hK8 expression and histological
grade lost their significance. There was significant relationship between
the hK8 expression status and KLK8 mRNA expression levels (p=0.0304).
Expression of hK8 is increased during the development of ovarian cancer and
down-regulated during ovarian cancer progression. Expression of hK8 is a
favorable prognostic marker in patients with ovarian cancer. PMID: 15138549 [PubMed -
indexed for MEDLINE] Br J Dermatol. 2005 Aug;153(2):274-81. Multiple
tissue kallikrein mRNA and protein expression in
normal skin and skin diseases. ¡P
Komatsu N,
Saijoh
K, Toyama T, Ohka R, Otsuki
N, Hussack
G, Takehara
K, Diamandis
EP. Department of Pathology and Laboratory Medicine,
Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada, M5G
1X5. BACKGROUND: Human tissue kallikreins
are a gene family (KLK1-KLK15) encoding for 15 secretory
serine proteases (hK1-hK15). Two tissue kallikrein
proteins, hK5 and hK7, were previously found in the stratum corneum (SC), stratum granulosum
(SG) and appendages. hK8 was also shown to be
secreted via lamellar granules and numerous KLK mRNAs were previously
identified. KLKs are believed to be responsible
for desquamation of corneocytes and sebum, sweat
and hair maturation. OBJECTIVES: To demonstrate immunohistochemically
the expression of hK6, hK8 and hK13 in normal skin tissue and to show an
increased cell number expressing kallikrein mRNAs
and proteins in psoriasis vulgaris (PV) and atopic dermatitis (AD). METHODS: Samples of normal, PV
and AD skin were obtained. hK6-, hK8- and
hK13-specific antibodies were produced and used for immunohistochemical
analysis. Multiple KLK mRNAs were synthesized and used for in situ
hybridization study. RESULTS: Three other hKs,
namely hK6, hK8 and hK13, were immunohistochemically
identified as new skin serine proteases in the whole SC, SG, sebaceous
glands, eccrine sweat glands, hair follicles and
nerves. We also demonstrated an increased number of cells expressing KLK
mRNAs and hKs in PV and AD. In PV, KLK mRNAs/hKs were predominantly expressed in the upper
epidermis. In AD, hK distribution was rather
diffuse and expanded into the lower epidermis. CONCLUSIONS: The colocalization of various hKs
seems to be essential for the regulation of serine protease activity in
skin and for steady desquamation and skin barrier function. Moreover, the
increased number of cells expressing multiple KLK mRNA and hK in PV and AD could be a clue to elucidate their
pathogenesis. PMID: 16086736 [PubMed -
indexed for MEDLINE] Genomics. 2006 Nov;88(5):591-9. Epub 2006 Jul 7. In silico identification and Bayesian phylogenetic
analysis of multiple new mammalian kallikrein
gene families. ¡P
Elliott MB,
¡P
Irwin DM, ¡P
Diamandis
EP. Department of Laboratory
Medicine and Pathobiology, Kallikrein gene families have been
identified previously in genomes of the human, the mouse, and the rat, and
individual kallikrein-like genes have been found
in many more species. This study presents the in silico
identification of kallikrein gene families in the
recently sequenced genomes of four additional mammalian species, the
chimpanzee, the dog, the pig, and the opossum. Phylogenies were constructed
with gene sequences from all seven mammalian families, using Bayesian
analysis, which clarified the evolutionary relationships between these
genes. Individual gene sequences, as well as concatenated constructs of
multiple sequences, were used. Fifteen kallikrein
genes were located in the chimpanzee (Pan troglodytes)
genome, while only 14 were identified in the canine (Canis
familiaris) genome as no orthologue
to human KLK3 was found. Thirteen genes were identified from the pig (Sus scrofa) genome, which
lacked homologues to KLK2 and KLK3, and 11 genes, orthologous
to human KLK5 through KLK15, were found in the opossum (Monodelphis
domestica) genome. No kallikrein
genes were identified from the available genome sequences of the chicken
(Gallus gallus) or African clawed frog (Xenopus tropicalis). Within
the family of kallikreins several subfamilies
were suggested by phylogenetic analysis. One
consisted of KLK4, KLK5, and KLK14; another of KLK9, KLK11, and KLK15; a third
of KLK10 and KLK12; a fourth of KLK6 and KLK13; and finally one of KLK8 and
the classical kallikreins (KLK1, KLK2, and KLK3). PMID: 16829021 [PubMed -
indexed for MEDLINE]